Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $8.30 million. The enterprise value is $8.35 million.
| Market Cap | 8.30M |
| Enterprise Value | 8.35M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026, after market close.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 21.57 million shares outstanding. The number of shares has increased by 208.91% in one year.
| Current Share Class | 21.57M |
| Shares Outstanding | 21.57M |
| Shares Change (YoY) | +208.91% |
| Shares Change (QoQ) | +3.87% |
| Owned by Insiders (%) | 12.86% |
| Owned by Institutions (%) | 5.83% |
| Float | 17.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.33 |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.18 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.17 |
Financial Efficiency
Return on equity (ROE) is -95.10% and return on invested capital (ROIC) is -50.33%.
| Return on Equity (ROE) | -95.10% |
| Return on Assets (ROA) | -46.97% |
| Return on Invested Capital (ROIC) | -50.33% |
| Return on Capital Employed (ROCE) | -102.99% |
| Weighted Average Cost of Capital (WACC) | 21.01% |
| Revenue Per Employee | $105,076 |
| Profits Per Employee | -$5.43M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.19% in the last 52 weeks. The beta is 2.05, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.05 |
| 52-Week Price Change | -82.19% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 42.47 |
| Average Volume (20 Days) | 455,117 |
Short Selling Information
The latest short interest is 521,424, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 521,424 |
| Short Previous Month | 632,502 |
| Short % of Shares Out | 2.42% |
| Short % of Float | 2.92% |
| Short Ratio (days to cover) | 0.87 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $315,227 and -$16.28 million in losses. Loss per share was -$1.10.
| Revenue | 315,227 |
| Gross Profit | 171,590 |
| Operating Income | -13.16M |
| Pretax Income | -15.10M |
| Net Income | -16.28M |
| EBITDA | -12.10M |
| EBIT | -13.16M |
| Loss Per Share | -$1.10 |
Balance Sheet
The company has $228,688 in cash and $279,207 in debt, with a net cash position of -$50,519 or -$0.00 per share.
| Cash & Cash Equivalents | 228,688 |
| Total Debt | 279,207 |
| Net Cash | -50,519 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 12.52M |
| Book Value Per Share | 0.70 |
| Working Capital | -1.15M |
Cash Flow
| Operating Cash Flow | -3.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.06M |
| Net Borrowing | -86,556 |
| Free Cash Flow | -3.89M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | 54.43% |
| Operating Margin | -4,173.65% |
| Pretax Margin | -4,791.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -208.91% |
| Shareholder Yield | -208.91% |
| Earnings Yield | -196.16% |
| FCF Yield | -46.88% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 16, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Mangoceuticals has an Altman Z-Score of -2.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 2 |